- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 27, 2023
Finance
April 27 Finance Quick Takes: Therini raises $36M A for fibrin-targeted therapies
Plus: Zura raises $80M, adds bifunctional asset in Lilly deal and updates from Foresite Diagnostics, Adcentrx, Pattern, Antiva and Mezzion
BioCentury | Mar 16, 2021
Product Development
The clinical pipeline for Alzheimer’s disease: Data Byte
The early stage Alzheimer’s pipeline moves beyond amyloid
BioCentury | Jan 28, 2020
Clinical News
Acceleron readout supports sotatercept as disease-modifying option for PAH
BioCentury | May 23, 2019
Emerging Company Profile
Obsidian: Fine-tuning therapeutic protein expression with approved drugs
How Obsidian is designing small molecule-controlled proteins for use in cell therapies and beyond
Items per page:
1 - 10 of 338